show add
hide add

Bicalutamide in the treatment of advanced prostatic carcinoma: a phase II multicenter trial


Abstract:

OBJECTIVES.

The safety, efficacy, and pharmacokinetics of the nonsteroidal antiandrogen bicalutamide were investigated in a Phase II trial in 150 patients with metastatic prostate cancer.

METHODS.

Patients took bicalutamide, 50 mg daily, in an open-label multicenter North American trial.

RESULTS.

The objective response rate (modified European Organization on Research and Treatment of Cancer [EORTC] criteria) was 70% (57% partial, 13% stable); 59 (39%) of 150 patients had either a > 90% decrease in prostate-specific antigen (PSA) levels or a decline to < 4 ng/mL. Extent of disease on the bone scan was a significant predictor of response. Patients with < 6 metastatic lesions were more likely to respond. Breast pain and gynecomastia occurred in 76% and 60% of patients, respectively. Gastrointestinal toxicity was very infrequent (diarrhea, 5%) The mean drug plasma concentration was 8528 (+/- 2928) ng/mL.

CONCLUSIONS.

Bicalutamide, 50 mg daily, was well tolerated and has efficacy in metastatic prostate cancer. The percentage of men who had > 90% decline in PSA levels is less than observed with surgical or medical castration and has led to trials using this antiandrogen at higher doses as monotherapy.

 

Author:

Soloway MS; Schellhammer PF; Smith JA; Chodak GW; Kennealey GT;

 

Source:

Urology, 47:1A, 1996 Jan, 33-7, discussion 48-53

 

Address:

Department of Urology, University of Miami School of Medicine, FL 33101, USA.

 

Language:

English

 

Unique Identifier:

96149764




READ THIS NEXT

    Shampoo for Women

    Blonde girl worried about hair loss

    ProTHIK Spray

    Tagamet (Cimetidine)

    Hair Loss Treatment

    man controls hair loss and unhappy gazing at you in the mirror 685775544 bald, baldness, loosing, prevention, hearttrob

    Male Pattern Alopecia

    Pin It on Pinterest

    Share This